论文部分内容阅读
1972年Sharp等报告一种系统性红斑狼疮(SLE)、系统性硬化症(PSS)和多发性皮肌炎的重叠综合征,考虑为“明确的风湿病综合征”,命名为“混合结缔组织病”(MCTD)。其特点是存在对核糖核酸酶敏感的抗可溶性核抗原(ENA)的抗体。ENA可分成两个明确的成分,即核糖核蛋白(RNA)和糖蛋白称“SM”抗原。诊断标准(1)有临床重叠发生的特点,(2)抗核免疫荧光斑点型≥1:480,(3)核糖核酸酶敏感的ENA血凝滴度≥1:6,400,(4)持久缺乏对双链DNA和SM抗原的抗体。作者观察20例MCTD,
In 1972, Sharp et al. Reported an overlapping syndrome of systemic lupus erythematosus (SLE), systemic sclerosis (PSS) and multiple dermatomyositis and considered “a definite rheumatism syndrome” as “mixed connective tissue Disease ”(MCTD). It is characterized by the presence of ribonuclease-sensitive anti-soluble nuclear antigen (ENA) antibodies. ENA can be divided into two distinct components, namely, ribonucleoprotein (RNA) and glycoprotein called “SM” antigen. Diagnostic criteria (1) have clinically overlapping features, (2) antinuclear immunofluorescence stains ≥1: 480, (3) ribonuclease-sensitive ENA titer ≥1: 6,400, (4) Antibodies to double-stranded DNA and SM antigens. The authors observed 20 cases of MCTD,